Wegovy 0.05mg: Is This a Real Dose, and What Should You Know?

Is 0.05mg actually part of the Wegovy schedule?

No. The five steps in the licensed UK Wegovy injection schedule are 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg. A 0.05mg figure doesn't correspond to any of them. It is five times smaller than the starting dose and has never formed part of the clinical programme. The most likely explanation is a decimal-point error (0.5mg misread as 0.05mg) which happens more often than you'd think when people are scanning unfamiliar medicine names and numbers at speed.

If you're feeling confused or frustrated by conflicting information you've found, that's entirely understandable. The landscape of GLP-1 medicines is genuinely complicated right now, with new dose formats, different brand names for the same molecule, and a lot of inaccurate content circulating online. The straightforward answer here is that 0.05mg simply doesn't exist in this medicine's schedule, so there's nothing to be concerned about if you haven't been offered it.

For a full map of the licensed steps, the Wegovy dose guide on this site covers each stage and what to expect during titration. The MHRA licenses these doses and the prescribing detail sits in the Summary of Product Characteristics published on the eMC.

What does the 0.25mg starting dose actually do?

The first pen (0.25mg weekly for four weeks) is there to settle your system, not to produce significant weight loss. Semaglutide slows gastric emptying and reduces appetite by acting on GLP-1 receptors; at a low introductory dose, those effects begin gently, which tends to reduce the nausea and digestive discomfort that can hit harder if you start at a higher level straight away.

This is why some people feel impatient at 0.25mg and wonder whether anything is happening. Clinically, it's doing its job. The prescriber will review how you're tolerating it before moving to the 0.5mg step, and progression continues on that roughly four-weekly rhythm up to the maintenance dose that suits you. Jumping doses or sourcing a different strength independently carries real risks, your digestive system hasn't had the chance to adjust, and side effects can become significantly harder to manage.

People sometimes ask whether they can skip the starter period if they've previously used a GLP-1 medicine. That's a clinical decision, not a general rule; a prescriber will assess your history before recommending anything.

How does the full schedule run from here, including the newer 7.2mg dose?

Once past 0.25mg, the standard titration moves through 0.5mg, then the 1mg step, which marks the midpoint of the titration and is where many people begin to notice more pronounced appetite changes, and 1.7mg before reaching 2.4mg, which was the established maintenance dose. In January 2026 the MHRA approved a higher 7.2mg maintenance dose for adults with obesity (BMI 30 or above), and a dedicated single-dose 7.2mg pen received approval on 14 April 2026. That higher dose, available as a pre-set once-weekly injection, is for those who tolerate 2.4mg and may benefit from greater efficacy; it's not a routine starting point and your prescriber determines whether it's appropriate.

The titration schedule means that the medicine you're taking in month one looks very different from the dose you might be on in month five. Understanding how Wegovy's dose steps work as a whole is genuinely useful, because questions about what to expect (and whether your current dose is 'working') are almost always tied to where you are in that progression. For context on what the evidence shows at maintenance doses, the STEP 1 trial published in the New England Journal of Medicine remains the landmark reference: around 15% average body-weight reduction over 68 weeks at 2.4mg weekly, a figure established before the 2mg formulation became available as an alternative presentation of the same therapeutic dose.

If you're weighing up the cost of treatment across those months, the Wegovy cost page explains how private pricing is structured in the UK and what an all-in price should typically cover.

Where does a prescriber fit into all of this?

Wegovy is a prescription-only medicine. No part of the dose schedule (starting it, moving through it, pausing it, or stopping it) sits with the patient alone. A GPhC-registered prescriber reviews your clinical information before any prescription is issued and before any dose increase is authorised. That's not bureaucracy for its own sake; it's how dose-related side effects are caught early and how treatment stays appropriate as your weight and health change.

At nume, every consultation is read by a named prescriber (a real clinician, same day) not routed through automated scoring. If you're already on Wegovy elsewhere and want to transfer, or if you're starting from scratch and want to understand whether you're clinically suitable, the process begins with a free assessment. Our clinical team can also answer dose-specific questions that aren't answered by the general guidance. If you're ready to take the next step, start your free consultation and a prescriber will review your information the same day.